All In Biotech

Drug Trial Radar · NCT05369767

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects

A Phase 1, Randomized, Double Blind, Dose-escalation, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

64

Actual

Start

May 24, 2022

Primary completion

Jan 30, 2023

Study completion Jan 30, 2023

Sponsor

Sponsor type
Industry
First posted
May 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of SHR-2004 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-2004 injection in healthy subjects.

Conditions

  • Prevention of Arterial and Venous Thrombosis

Interventions

  • SAD, SHR-2004Drug

    Ascending dose

  • SAD, SHR-2004 placeboDrug

    Ascending dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the number of subjects with adverse events (AEs) and serious adverse events (SAEs)Time frame: up to day 113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Drum Tower Hospital of Nanjing University Medical school

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.